Tax & Penalty28 Jul 2026, 07:21 pm
AstraZeneca Pharma India Receives ₹79.97 Lakh Demand Notice from NPPA
AI Summary
AstraZeneca Pharma India Ltd has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging of ₹79,97,457, including interest, on Betaloc-50 (Metoprolol 50 mg tablets). The NPPA alleges that the company sold the drug at a price higher than the notified ceiling price and failed to implement revised ceiling prices on existing stocks. The overcharging is alleged to have occurred between June and July 2016. The company is reviewing the notice and will take appropriate legal steps.
Key Highlights
- NPPA issued a demand notice for alleged overcharging of ₹79.97 Lakhs.
- Allegation pertains to Betaloc-50 sales above notified ceiling prices.
- Company is reviewing the notice and will take legal action.
- Demand includes interest calculated up to August 10, 2026.
Price Impact
More from ASTRAZEN